<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="308312">
  <stage>Registered</stage>
  <submitdate>5/08/2009</submitdate>
  <approvaldate>6/08/2009</approvaldate>
  <actrnumber>ACTRN12609000673246</actrnumber>
  <trial_identification>
    <studytitle>Dextran in Carotid Endarterectomy Trial</studytitle>
    <scientifictitle>A Multicentre, Randomised, Placebo contolled trial of intravenous 10% Dextran 40 (Rheomacrodex), in the Prevention of Stroke in Carotid Surgery</scientifictitle>
    <utrn />
    <trialacronym>DICE</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Carotid Endarterectomy and Thromboembolism</healthcondition>
    <conditioncode>
      <conditioncode1>Stroke</conditioncode1>
      <conditioncode2>Ischaemic</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Administered at the induction of anaesthesia for carotid endarterectomy, the trial intervention consists of an initial bolus of 20ml of dextran 1 (promit) or normal saline placebo given intravenously followed by intravenous infusion of 10% dextran 40 or normal saline placebo at an infusion rate of 125 ml/hr for 4 hours then 42 ml/hr for a further 12 hours.</interventions>
    <comparator>10% Dextran 40 (rheomacrodex) verses placebo (normal saline)</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Ipsilateral fatal and non-fatal stroke, hemispheric or retinal</outcome>
      <timepoint>At 30 days post-intervention</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Ipsilateral Transient Ischaemic Attack (TIA)</outcome>
      <timepoint>At 30 days post-intervention</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Any non-fatal or fatal stroke</outcome>
      <timepoint>At 30 days post-intervention</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death due to any cause</outcome>
      <timepoint>At 30 days post-intervention</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Unstable angina or non-fatal myocardial infarction</outcome>
      <timepoint>At 30 days post-intervention</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Symptomatic or a symptomatic carotid artery atherosclerosis considered suitable for Carotid Endarterectomy (CEA) performed under either general or loco-regional anaesthesia.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Documented history of congestive cardiac failure New York Heart Association Functional Classification equal to or greater than 3 (NYHA=/&gt;GD 3), unstable angina or acute myocardial infarction within 3 months of surgery.
Renal impairment as measured by a serum creatinine of greater than 0.20 mmol/l.
Thrombocytopaenia of less than 100,000/mm3.
Previous hypersensitivity to dextrans.
Concomitant ipsilateral balloon and/or stenting procedure with CEA.    
Patients remaining on warfarin during surgery and those who will receive concomitant heparin therapy post-operatively are also excluded.  Patients who are treated with warfarin (without heparin) may be included if the International Normalised Ratio (INR) on the day of surgery is below 1.5.
Lack of informed consent.
Combined CEA/Coronary Artery Bypass Grafts (CABGs) procedure.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>A central randomisation centre is located at the Austin Hospital Pharmacy Department.  The Pharmacy Department at each centre will maintain an additional log of patient details and treatment allocation for purposes of cross checking or unblinding of patients in the event of a serious adverse outcome.  Any patients who are randomised, but do not follow protocol for whatever reason, are still followed up by the intention-to-treat principle.</concealment>
    <sequence>Following the informed consenting process, participants are assigned consecutively to next study allocation (treatment or placebo). The allocation log was generated using random number generating software.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/01/2002</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>1412</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>National Stroke Research Institute and John Hunter Health</primarysponsorname>
    <primarysponsoraddress>L1 Neurosciences Building,Heidelberg Repatriation Hospital, 300 Waterdale Road Heidelberg Heights, Victoria 3081</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Austin Health Human Research Ethics Committee</ethicname>
      <ethicaddress>Henry Buck Building, Austin Hospital, 30 Studley Road, Heidelberg Victoria 3084</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Christopher Levi</name>
      <address>First Floor, Hunter Rehabilitation Service Buiding, John Hunter Hospital Campus, Locked Bag No.1, Hunter Region Mail Centre, NSW 2310</address>
      <phone>+61 2 4985 5593</phone>
      <fax>+61 2 4921 4833</fax>
      <email>Christopher.Levi@hnehealth.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dennis Young</name>
      <address>Trial Coordinator
National Stroke Research Institute
Level 1, Neurosciences Building
Heidelberg Repatriation Hospital
300 Waterdale Road
Heidelberg Heights Vic 3081</address>
      <phone>+61 3 9496 2648</phone>
      <fax>+61 3 9496 2650</fax>
      <email>dyoun@nsri.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dennis Young</name>
      <address>Trial Coordinator
National Stroke Research Institute
Level 1, Neurosciences Building
Heidelberg Repatriation Hospital
300 Waterdale Road
Heidelberg Heights Vic 3081</address>
      <phone>+61 3 9496 2648</phone>
      <fax>+61 3 9496 2650</fax>
      <email>dyoun@nsri.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>